[Coronary stents].
Since the introduction of coronary stents into clinical practice in the late 1980s, the number of stent implantations has increased so rapidly that stents are currently used in over 80 percent of all percutaneous coronary interventions. Although stent implantation was initially limited to large vessels with proximal and discrete lesions, improvements in stent design and implantation technique now allow their deployment in more complex lesions in smaller and diffusely diseased vessels. The overall acceptance of stents by interventional cardiologists can be attributed to favorable acute and longterm results compared to balloon angioplasty alone. Interventionalists have also been quick to embrace the smoother and larger lumen after stenting, in a shorter procedure time and with no additional risk, especially since the risk of stent thrombosis has been overcome by the introduction of dual antiplatelet therapy with Aspirin and Ticlopidine or Clopidogrel. Although restenosis and the need for reinterventions is lower after stenting compared to balloon angioplasty it still remains significant with about 15 percent of all patients returning for an other revascularization procedure. Meanwhile, a completely new generation of stents promises to eliminate the problem of restenosis. Drug-eluting stents, coated with antiproliferative substances have been successfully tested in small randomized trials. The restenosis rates at 6 and 12 months were extremely low ranging between zero and nine percent, with no clinical drawbacks so far. If these results hold up in longer follow up and in real life practice with more complex lesions stented the treatment of symptomatic coronary artery disease will change even more dramatically.
Herz-Gefässzentrum Zürich, Klinik im Park, Zürich. franz.amann@hirslanden.ch
F W
FW
Amann
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D011474:Prosthesis Design; D012086:Reoperation; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D017239:Paclitaxel; D020123:Sirolimus